LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO MT
Oxford Biomedica Names New Finance Chief MT
K3 Business sees interim revenue decline AN
MorphoSys Informs Nasdaq Stock Market of Delisting Plans After Novartis Merger MT
Novartis Seeks Squeeze Out Approval at MorphoSys AGM MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
INDEX-MONITOR: Tui, Rational and Traton in the MDax - Douglas moves up to the SDax DP
MorphoSys AG(XTRA:MOR) dropped from Germany MDAX Index (Performance) CI
MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX (Total Return) Index CI
MorphoSys AG(XTRA:MOR) dropped from Germany TECDAX Index (Price Return) CI
Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15 DP
Novartis: towards the filing of a buyout offer for MorphoSys CF
MorphoSys Set to Delist Following Acquisition by Novartis MT
MorphoSys Inks Delisting Agreement After Takeover by Novartis MT
Biotech company Morphosys will soon disappear from the stock exchange RE
MorphoSys to Leave Deutsche Börse’s MDAX, TecDAX Indices MT
MorphoSys AG(XTRA:MOR) dropped from S&P Global BMI Index CI
MorphoSys AG Announces Board Changes CI
MorphoSys AG Appoints Arkadius Pichota as Chief Executive Officer CI
MorphoSys AG Appoints Lukas Gilgen as CFO CI
Three newcomers to the MDax - Rational, TUI and Traton move up RE
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
SMA Solar and Morphosys are about to leave the MDax RE
Novartis data42 AG completed the acquisition of MorphoSys AG from group of shareholders. CI
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading MT
Chart MorphoSys AG
More charts
Logo MorphoSys AG
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Employees
464
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
67.75EUR
Average target price
58.71EUR
Spread / Average Target
-13.34%
Consensus
  1. Stock Market
  2. Equities
  3. MOR Stock
  4. News MorphoSys AG
  5. MorphoSys to Leave Deutsche Börse’s MDAX, TecDAX Indices